Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.859
-0.004 (-0.44%)
At close: Mar 6, 2026, 4:00 PM EST
0.842
-0.017 (-1.98%)
After-hours: Mar 6, 2026, 6:44 PM EST
Biofrontera Employees
As of December 31, 2024, Biofrontera had 93 total employees, including 92 full-time and 1 part-time employees. The number of employees increased by 8 or 9.41% compared to the previous year.
Employees
93
Change (1Y)
8
Growth (1Y)
9.41%
Revenue / Employee
$399,613
Profits / Employee
-$188,946
Market Cap
10.01M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 93 | 8 | 9.41% |
| Dec 31, 2023 | 85 | 4 | 4.94% |
| Dec 31, 2022 | 81 | 12 | 17.39% |
| Dec 31, 2021 | 69 | 13 | 23.21% |
| Dec 31, 2020 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IM Cannabis | 95 |
| Aytu BioPharma | 83 |
| Sunshine Biopharma | 52 |
| cbdMD | 42 |
| RedHill Biopharma | 35 |
| InMed Pharmaceuticals | 13 |
| Gelteq | 8 |
| Sonoma Pharmaceuticals | 8 |
BFRI News
- 9 days ago - U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable - GlobeNewsWire
- 18 days ago - Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities - GlobeNewsWire
- 24 days ago - Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma - GlobeNewsWire
- 26 days ago - Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint - GlobeNewsWire
- 7 weeks ago - Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth - GlobeNewsWire
- 2 months ago - Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones - GlobeNewsWire
- 2 months ago - Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio - GlobeNewsWire
- 3 months ago - Last Patient Completes Biofrontera's Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities - GlobeNewsWire